WZ8040 is a novel EGFR inhibitor which suppresses the growth of EGFR-T790M-containing cell lines and inhibits EGFR phosphorylation. WZ8040 has a basic chemical framework (covalent pyrimidine) which is different from that of other EGFR inhibitors. WZ8040 is 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wildtype EGFR, than quinazoline-based EGFR inhibitors (HKI-272 and CL-387,785) in vitro.
 |
Source | Nature (2009). Figure 2. WZ8040 |
| Method | Immunohistochemical analysis | |
| Cell Lines | 3T3 cells | |
| Concentrations | 10 ng/ml | |
| Incubation Time | 16 h | |
| Results | These compounds were 3- to 100-fold less potent, with WZ compounds being least potent, than CL-387,785 and HKI-272 at inhibiting the growth of the EGFR WT cells. |
 |
Source | Nature (2009). Figure 1. WZ8040 |
| Method | immunoblot | |
| Cell Lines | PC9 GR cells | |
| Concentrations | 10 ng/ml | |
| Incubation Time | 16 h | |
| Results | We observed a similar increased potency of the WZ compounds in the H1975 (L858R/T790M) cell line and in Ba/F3 cells harbouring EGFR T790M |
| Cell Experiment | |
|---|---|
| Cell lines | NSCLC or Ba/F3 cells |
| Preparation method | Cell proliferation and growth assays NSCLC or Ba/F3 cells were exposed to treatment for 72 hours and the number of cells used per experiment determined empirically and has been previously established2,7. All experimental points were set up in six to twelve wells and all experiments were repeated at least three times. The data was graphically displayed using GraphPad Prism version 5.0 for Windows, (GraphPad Software; www.graphpad.com). The curves were fitted using a non-linear regression model with a sigmoidal dose response. |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | EGFR-TL (T790M/L858R) mice and EGFR exon19 Deletion-T790M (TD) inducible bitransgenic mice |
| Formulation | NMP (10% 1-methyl-2-pyrrolidinone: 90% PEG-300) |
| Dosages | 25mg/kg daily |
| Administration | gavage |
| Molecular Weight | 481.01 |
| Formula | C24H25ClN6OS |
| CAS Number | 1214265-57-2 |
| Solubility (25°C) | DMSO 76 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Zhou W, et al. Nature. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
| Related EGFR/HER2 Products |
|---|
| BBT-207
BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity. |
| VRN-11
VRN-11 is an EGFR C797S inhibitor. |
| TRX-221
TRX-221 is an EGFR C797S inhibitor. |
| TAS-3351
TAS-3351 is an EGFR C797S inhibitor. |
| Larotinib mesylate hydrate
Larotinib mesylate hydrate is a potent, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) that primarily targets EGFR with an IC50 of 0.6 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
